ANI Pharmaceuticals | ANIP - Operating Profit


ANI Pharmaceuticals reported $22.83M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
ANI Pharmaceuticals USD 22.83M 7.66M Sep/2025
Assertio Holdings USD -3.05M 569K Sep/2024
Aurora Cannabis CAD -55.67M 35.45M Sep/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Heron Therapeutics USD -5.66M 782K Sep/2024
Hikma Pharmaceutical USD 187M 95M Jun/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novartis USD 4.58B 879M Sep/2025
Omeros USD -35.41M 23.75M Sep/2024
Perrigo USD 93.4M 37.8M Sep/2025
Sun Pharmaceuticals INR 33.67B 49.9M Sep/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025